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Abstract Heart failure is characterised by reduced
expression of sarcoplasmic reticulum calcium-ATPase
(SERCA) and increased expression of B-type natriuretic
peptide (BNP). The present study was performed to inves-
tigate causality of this inverse relationship under in vivo
conditionsinthetransversalaorticconstrictionmousemodel
(TAC). Left ventricular SERCA-mRNA expression was
signiﬁcantly upregulated in TAC by 32% after 6 h, but not
different from sham after 24 h. Serum proANP and BNP
levels were increased in TAC after 24 h (BNP ?274%,
p\0.01; proANP ?60%, p\0.05), but only proANP
levels were increased after 6 h (?182%, p\0.01). cGMP
levels were only increased 24 h after TAC (?307%,
p\0.01),butnot6 hafterTAC.BNPinfusioninhibitedthe
increase in SERCA expression 6 h after TAC. In BNP-
receptor-knockout animals (GC-A), the expression of
SERCA was still signiﬁcantly increased 24 h after TAC at
the mRNA level by 35% (p\0.05), as well as at the protein
levelby25%(p\0.05).MCIPexpressionasanindicatorof
calcineurinactivitywasregulatedinparalleltoSERCAafter
6 and 24 h. MCIP-mRNA was increased by 333% 6 h after
TAC, butnot signiﬁcantly different from sham after 24 h. In
the GC-A-KO mice, MCIP-mRNA was signiﬁcantly
increased in TAC compared to WT after 24 h. In mice with
BNP infusion, MCIP was signiﬁcantly lower 6 h after TAC
comparedtocontrolanimals.Inconclusion,mechanicalload
leads to an upregulation of SERCA expression. This is fol-
lowed by upregulation of natriuretic peptides with sub-
sequent suppression of SERCA upregulation. Elevated
natriuretic peptides may suppress SERCA expression by
inhibition of calcineurin activity via activation of GC-A.
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Introduction
In heart failure, a reactivation of the foetal gene expression
programme is observed [4]. Accordingly, the level of
B-type natriuretic peptide (BNP) is increased [37], and the
expression and function of calcium cycling proteins is
changed [11, 23, 33]. In particular, the expression of sar-
coplasmic reticulum Ca
2?-ATPase (SERCA) is reduced
[10]. Induction of the foetal gene programme is considered
to result from increased myocardial load. However, in
contrast to this general scheme of reactivation of the foetal
gene programme with SERCA downregulation, we have
previously demonstrated in an in vitro model that increased
load immediately increases SERCA expression. Moreover,
load-dependent upregulation of SERCA could be abolished
by addition of exogenous BNP. This effect was transmitted
via the BNP receptor guanylyl cyclase A (GC-A), elevation
of cyclic guanosine monophosphate (cGMP) and activation
of protein kinase G (PKG) [17]. PKG has effects on con-
tractile function [21] and on signalling mechanisms. PKG
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dependent upregulation of SERCA expression could indeed
be inhibited by cyclosporine A [17].
In the present study, we evaluated the role of load and
BNP on early SERCA regulation under in vivo conditions.
Methods
Animals
The investigation conforms to the Guide for the Care and
Use of Laboratory Animals (NIH publication No. 85–23,
revised 1996) and was performed in accordance with the
ethical standards laid down in the Declaration of Helsinki
1964. For the present study, the following mice strains
were used: FVBN (Charles River), NFAT-luciferase
transgenic [38], GC-A-KO mice [15], muscle LIM protein
knockout (MLP-KO) [2] mice and wild-type littermates.
Only female mice were included in the study due to the
higher mortality after Transversal aortic constriction
(TAC) in male mice.
Transversal aortic constriction
Surgery was performed using a minimally invasive
approach as described previously [16]. Brieﬂy, 12-week-
old female FVBN mice were anesthetised using intraperi-
toneal injections of ketamine and xylazine (100 mg/
kg ? 5 mg/kg). A horizontal incision at the jugulum was
used to display the transversal aorta. A 27-gauge needle
was tied against the aorta using a 5-0 non-absorbable
suture. After removal of the 27-gauge needle, skin was
closed, and the mice were kept on a warming plate until
recovery from anaesthesia. Sham animals underwent the
same procedure except banding of the transversal aorta. At
the end of the experiment, mice were euthanised by iso-
ﬂuran insufﬂation.
Osmotic minipump application of BNP
Osmotic minipumps (1003D, ALZET, Cupertino, CA,
USA) were ﬁlled with a recombinant mouse BNP-peptide
(Phoenix Pharamaceuticals, St. Jospeh, MO, USA) or a
saline solution. The pump rate was 0.22 lg BNP/h. Mice
were distributed to the following four groups: group I:
Sham with saline infusion; group II: Sham with BNP
infusion; group III: TAC with saline infusion; group IV:
TAC with BNP infusion. The minipumps were primed and
implanted 12 h before the TAC operation. The hearts of the
animals were excised 6 h after the operation and harvested
in liquid nitrogen.
Echocardiography
A 2D-guided M-mode echocardiography was performed
usingaVS-VEVO660/230HighResolutionImagingSystem
(Visualsonics, Toronto, Canada). Mice were lightly anesthe-
tised with 2.5% 2-2-2-tribromoethanol (avertin, 0.01 ml/g
i.p.) and were allowed to breathe spontaneously. LV end-
diastolic (LVEDD) and end-systolic (LVESD) dimensions
were measured from original tracings by using the leading
edge convention of the American Society of Echocardiogra-
phy. LV percent fractional shortening (FS) and LV mass
(LVM) were calculated as previously described [29].
Quantitative mRNA measurement in the mouse
myocardium
DNA-free total RNA was extracted from myocardial
samples by a standard protocol with the RNeasy kit and
RNase-free DNAse Set (Qiagen, Hilden, Germany). First-
strand cDNA synthesis was carried out with iScript cDNA
synthesis kit (BioRad, Mu ¨nchen, Germany) according to
manufacturer’s instructions. Real-time polymerase chain
reactions (PCRs) were performed on a Biorad iQ-Cycler in
a volume of 20 lL in a 96-well plate. The reaction mixture
consisted of 1 ll cDNA with 19 ll SYBR GRN SUPER-
MIX (BioRad, Mu ¨nchen, Germany). After initial denatur-
ation for 60 s at 95C, the cycling programme consisted of
40 cycles of 95C for 15 s, 60C for 10 s and 72C for
15 s. Emission at 530 nm was measured at the end of each
cycle. Primer sequences used were: GAPDH sense: GC
AGTGGCAAAGTGGAGATT, antisense: TCTCCATGG
TGGTGAAGACA; ANP sense: TGATAGATGAAGGCA
GGAAGCCGC, antisense: AGGATTGGAGCCCAGAGT
GGACTAGG; BNP sense: TCTCCAGAGCAATTCAAG
AT, antisense: AACAACTTCAGTGCGTTACA; SERCA
sense: AGATGGTCCTGGCAGATGAC, antisense: GTCC
AGGTCTGGAGGATTGA; MCIP sense ACTGGAAGG
TGGTGTCCTTGTC, antisense: TCCAGCTTGGGCTT
GACTGAG. cDNAs with known concentrations were used
to generate quantiﬁcation standard curves. Expression data
were normalised to GAPDH.
Luciferase enzymatic assay
Luciferase enzymatic activity in the tissue extracts was
measured by a commercial kit (luciferase reporter gene
assay, high sensitivity, Roche, Mannheim, Germany)
according to the manufacturer’s indications. The light
intensity was measured with a luminometer (Mithras LB
940, Berthold Technologies, Bad Wildbad, Germany) and
expressed as relative light units (RLU) over micrograms of
protein.
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in the myocardium
The BNP (BioSupply UK, Bradford, UK) and proANP
(Biomedica, Wien, Austria) were measured in serum of the
mice collected by excision of the heart. cGMP was mea-
sured by ELISA in homogenated left ventricular tissue (GE
Healthcare, Chalfont St. Giles, UK). The ELISAs were
done according to the manufacturer’s instructions.
Western immunoblot analysis
Frozen muscle strips or pieces of the left ventricle were
thawed on ice in 50 lL of homogenisation buffer and
homogenised. Protein concentrations of the suspensions
were determined, and 20 lg of samples subjected to SDS-
PAGE. Western blotting was carried out according to
standard protocols, using antibodies against SERCA (ABR,
Rockford, USA) PLB (Badrilla, Leeds, UK), phosopho-
PLB (Badrilla, Leeds, UK) and GAPDH (BioTrend,
Cologne, Germany). For quantiﬁcation, an enhanced che-
moluminescence detection system (Amersham) was used
according to the manufacturer’s instructions.
Calculation and statistical analysis
Gene- and protein-expression was analysed using two-way-
ANOVA or unpaired Student’s t test with values of
p\0.05 considered statistically signiﬁcant. Numbers of
experiments are indicated in the ﬁgure legend in the fol-
lowing order: Sham/TAC or WT-Sham/-WT-TAC/KO-
Sham/KO-TAC.
Results
Load-dependent regulation of SERCA
SERCA-mRNA expression is upregulated in vivo after 6 h
by 32% in TAC (p\0.05; Fig. 1). After 24 h, the
expression of SERCA has returned to the sham level
(Fig. 1).
Load-speciﬁc regulation of natriuretic peptides
Six hours after TAC, the serum level of ANP (?182%;
Fig. 2a), but not BNP (Fig. 2b), was signiﬁcantly increased
compared to control. Serum levels of BNP and pro ANP
were elevated 24 h after TAC (proANP: ?60%, p\0.05;
BNP: ?274%, p\0.01; Fig. 2c, d). The main source of
ANP and BNP 24 h after TAC is the left ventricle (BNP
?507% p\0.05; Fig. 3a). The expression of BNP was
paralleled by ANP, only with lower amplitude (Fig. 3b).
Regulation of the cGMP level by load
Six hours after TAC, the cGMP level showed only a ten-
dency to be increased, but 24 h after TAC a clear increase
in cGMP could be shown (?307%; Fig. 4a).
Inﬂuence of the particulate guanylyl cyclase on SERCA
regulation
We tested the hypothesis that BNP would depress load-
dependent SERCA upregulation at time periods longer than
6 h following surgery. For this purpose, we used geneti-
cally modiﬁed animals lacking the guanylyl cyclase-A
(GC-A, BNP receptor) in cardiomyocytes. Indeed, in those
animals, SERCA upregulation was still preserved 24 h
following TAC (Fig. 4b). This hypothesis is further sup-
ported by the ﬁnding that application of BNP via osmotic
mini pumps prevented SERCA-mRNA upregulation 6 h
after TAC (Fig. 4c).
The SERCA regulation by load and its BNP-dependent
depression was detectable at the protein level as well. 24 h
after TAC, protein levels of SERCA were signiﬁcantly
higher in GC-A-KO compared to WT animals. Conversely
6 h after TAC, protein levels of SERCA were signiﬁcantly
lower in animals with continuous infusion of BNP (Fig. 5a,
b). Phospholamban (PLB) expression was not changed
after 6 and 24 h (Fig. 5a, c), and phosphorylation of PLB
was increased after 24 h in both WT and GC-A-KO ani-
mals after TAC to a comparable degree (Fig. 5a, d).
Analysis of in vivo contractile function
in the GC-A-KO animals
We previously could show that increased SERCA expres-
sion in our in vitro model leads to an improved force–
frequency relationship [17]. Here, we studied the contractile
function in the pressure-overloaded GC-A-KO and control
mice 24 h after TAC. No decrease in fractional shortening
(FS) could be seen in WT-TAC compared to control
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Fig. 1 Regulation of SERCA expression following TAC. mRNA
expression of SERCA 6 h (n = 6/6) and 24 h (n = 6/6) after the
intervention. TAC increased SERCA expression by 32% after 6 h
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the pressure-overloaded heart. Also the GC-A-KO-TAC
animals showed a similar FS compared to WT-TAC.
Regulation of SERCA via NFAT
Evidence from in vitro studies from us and other groups
suggest that SERCA regulation may occur via calcineurin–
NFAT (CN) activation [1, 17]. We measured NFAT-
luciferase activity and MCIP expression as parameters of
calcineurin activation in vivo. Both MCIP expression and
NFAT-luciferase activity were elevated in the TAC model
after 6 h indicating CN activation. After 24 h, MCIP
expression and NFAT-luciferase activity returned to nor-
mal (Fig. 7a, b). Again, MCIP expression was regulated in
parallel to SERCA expression in the GC-A-KO animals
and in mice with BNP infusion. MCIP expression after
TAC was still increased in GC-A-KO mice after 24 h
(TAC-WT vs. TAC-KO ?106%, p\0.05; Fig. 7c) and
reduced in mice with BNP infusion after 6 h (TAC saline
vs. TAC BNP -62%, p\0.05; Fig. 7d). This shows that
calcineurin activation occurs in parallel to SERCA regu-
lation at an early timepoint, suggesting an important role
of calcineurin for SERCA upregulation under in vivo
conditions.
Load-dependent regulation of SERCA and BNP
expression in MLP-KO mice
The load-dependent regulation of SERCA and BNP was
analysed in the MLP-KO-mouse heart failure model. At the
age of 12 weeks, when the TAC procedure was performed,
there was a clear upregulation of BNP (p\0.01) and a
downregulation of SERCA (-37%, p\0.01) in the MLP-
KO compared to the wild-type mice.
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Fig. 3 Source of the natriuretic peptides: expression of BNP (a) and
ANP (b) following TAC normalised to sham in the left (LV) and right
(RV) ventricle and the left (LA) and the right (RA) atrium 24 h after
intervention (per chamber: n = 6/6); *p\0.05 TAC versus Sham
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123The TAC induced an upregulation of BNP in wild type
(?506%, p\0.05) and MLP-KO (?325%, p\0.01;
Fig. 8a). The SERCA upregulation after 6 h was only
demonstrable in the wild type (?34%, p\0.05), but not in
the MLP-KO mice (Fig. 8b).
Discussion
The present data show that acute hemodynamic load fol-
lowing aortic constriction results in transient upregulation
of SERCA. SERCA upregulation is associated with MCIP
expression indicating increased calcineurin (CN) activity.
Subsequent decrease of SERCA expression is due to
increased expression of ANP and BNP and subsequent
activation of the guanylyl cyclase receptor. We conclude
that load immediately upregulates SERCA mediated by CN
activation and that subsequent BNP expression results in
downregulation of SERCA through cGMP-dependent
inhibition of CN. The present in vivo data are consistent
with previous in vitro studies and support the hypothesis
that BNP may be involved in the downregulation of
SERCA as it occurs with persistent increase in hemody-
namic load.
Mechanisms of SERCA upregulation
and hemodynamic relevance
The SERCA upregulation was correlated with MCIP
expression and with increased NFAT-luciferase activity.
We did not show a direct proof for regulation of SERCA
via NFAT in vivo, but previously we [17] and others
[1] could show that calcineurin–NFAT is involved in
SERCA upregulation. Calcineurin transgenic mice show
an increased SERCA protein expression [5]. In vitro
experiments in cells transfected with different SERCA-
promoter-luciferase constructs showed that NFAT in
combination with MEF2 induced an upregulation of the
luciferase activity in long promoter constructs (6.6 kb)
[35]. Here, we found that NFAT activity is increased in
parallel with SERCA regulation at short time intervals
(6 h) and may therefore be important for an adaptive
hypertrophic response. The concept of an early beneﬁcial
effect of calcineurin is also supported by the fact that a
load-dependent increase in proteins involved in energy
metabolism occurs through calcineurin [30]. Favourable
effects of calcineurin activation are also reported from
calcineurin-Aß-knockout mice which show apoptosis and
a worse prognosis after myocardial infarction [3]. In
contrast to short-term CN effects, long-term activation is
considered harmful [25].
Beneﬁcial and unfavourable effects of BNP
Experimental ﬁndings from transgenic animals implicate
that the BNP-GC-A-cGMP signal pathway mediates ben-
eﬁcial effects on the heart. BNP has antihypertrophic and
antiﬁbrotic effects [19]. In addition, it has also been shown
that BNP stimulates angiogenesis in the pressure-over-
loaded heart [20]. Activation of PKG by BNP via GC-A [9]
has also cardioprotective effects by inﬂuencing mitochon-
drial pore opening [13, 14]. Loss of the GC-A receptor in
the heart increases the susceptibility to heart failure in PO
[15, 26, 27, 34]. From this point of view, one may speculate
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Fig. 4 Inhibition of load-dependent SERCA-mRNA upregulation by
the BNP-GC-A signal pathway. a Myocardial cGMP level 6 and 24 h
after TAC (n = 6/6/6/6). b SERCA-mRNA expression 24 h after
TAC in WT and GC-A-KO mice (n = 8/11/10/14). SERCA is
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123that teleologically BNP may have a protective role on load-
induced hypertrophy. Along the same direction, downreg-
ulation of SERCA may be beneﬁcial reducing energy
consumption for excitation–contraction coupling and
myoﬁlament activation. This, however, would occur at the
price of reduced contractility. Here, we show that BNP has
a negative effect on SERCA regulation in vivo. This is
consistent with our previous in vitro results [17] and with
Sodi et al. [32]. They also found that in isolated rat cells
BNP treatment reduced SERCA expression. We could
show that in heart failure patients treated with a left ven-
tricular assist device (LVAD), SERCA was only upregu-
lated in the subgroup of patients in whom BNP-expression
was reduced by this therapy. In the subgroup with sustained
BNP elevation, SERCA expression was not changed [17].
The effect of BNP on SERCA expression may be also
relevant when BNP (Nesiritide) is used to treat heart failure
in patients. Nesiritide is used to treat acute decompensated
heart failure. Of note, a meta-analysis of Sackner-Bernstein
et al. [28] showed an increased mortality in patients treated
with Nesiritide; however, mortality was not increased in
other studies with short Nesiritide application [7]. Pro-
longed treatment of Nesiritide has not been studied so far.
Differences between ANP and BNP
Both natriuretic peptides activate the same guanylyl
receptor (GC-A) and lead to an increase in cGMP. Here,
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BNP inhibited the load-induced SERCA upregulation.
The increase of the natriuretic peptides after 24 h might
mostly be due to ventricular synthesis of BNP and ANP.
Other groups could show that stretch leads to an increased
BNP promoter activation after 30 min [12] and an
upregulation of BNP mRNA expression in vitro already
after 6 h in the culture medium of isolated stretched cells
[22]. We analysed the in vivo expression of ANP and
BNP in the serum by a non-radioactive ELISA. Using a
radioimmunoassay might have a higher sensitivity, and
therefore, an increase in BNP might be detected earlier.
Also the experiments were done in vitro, while we mea-
sured the concentration in the blood in vivo. The BNP
synthesis in the cardiomyocytes takes a certain time
during which the inhibitory action of BNP via GC-A is
not present in the heart. At later timepoints (24 h and
later), enough BNP is produced to induce the known BNP
effects.
The ANP seems to have another role for the cardio-
vascular system. Here, we could show that proANP
expression in the blood was increased after 6 h, but this
did not lead to an increase in myocardial cGMP and an
inhibition of SERCA upregulation by load. This indicates
that serum ANP might predominantly have extracardiac
functions. The increase in ANP 6 h after load might be
explained by the release of stored ANP in the granula of
the atrial myocytes [6]. Reason for the lack of systemic
ANP on myocardial SERCA regulation could be the
higher degradation of ANP in the heart. The neutral
endopeptidase (NEP) and also the natriuretic peptide
clearance receptor (GC-C) have a higher afﬁnity to ANP,
and therefore, systemic ANP might be faster degraded
[31, 36]. So, the function of ANP might be more focused
on renal and vascular actions of the natriuretic peptides,
whereas BNP seems to have mostly local myocardial
functions [18].
Mechanism of BNP-mediated SERCA downregulation
Activation of PKG by BNP via GC-A leading to cGMP
elevation is an important signal pathway of the natriuretic
peptides [32]. Our data support the notion that GC-A is
involved in suppression of SERCA expression by BNP. As
shown recently, the regulation of SERCA by BNP involves
cGMP and activation of PKG [17] and PKG can inhibit
calcineurin activation [8]. This is consistent with our data
suggesting relevance of CN in load-dependent SERCA
regulation. We suggest that BNP inhibits CN activation and
thereby suppresses the load-dependent CN-mediated
upregulation of SERCA. The inhibitory action of BNP on
CN activation is probably induced by a PKG-induced
reduction of Ca
2? transients [24, 39].
Conclusion
The SERCA is regulated by load in vivo. The upregulation
of SERCA occurs via an activation of the calcineurin–
NFAT pathway and is inhibited by BNP acting via the GC-
A receptor. Therefore, short activation of calcineurin may
be beneﬁcial for adaptation to acute increases in hemody-
namic load.
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